Novel class of compounds for MS and CNS disorders
Posted: Wed Jun 12, 2013 6:22 am
Aphios USA and VivaCell Spain to develop novel class of compounds for MS and CNS disorders
Aphios Corporation, today announced that it has entered into joint Research Collaboration and Commercialisation Agreements with VivaCell Biotechnology EspaƱa S.L., Cordoba, Spain to develop therapeutics for multiple sclerosis and other neurodegenerative diseases of the central nervous system (CNS)......... Read More - http://www.ms-uk.org/index.cfm/cannabisresearch
Aphios Corporation, today announced that it has entered into joint Research Collaboration and Commercialisation Agreements with VivaCell Biotechnology EspaƱa S.L., Cordoba, Spain to develop therapeutics for multiple sclerosis and other neurodegenerative diseases of the central nervous system (CNS)......... Read More - http://www.ms-uk.org/index.cfm/cannabisresearch